Opthea gets positive feedback from European regulatory groups for wet-AMD injection

Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration.

The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intravitreal injections.

Get the full story at our sister site, Drug Delivery Business News.

The post Opthea gets positive feedback from European regulatory groups for wet-AMD injection appeared first on MassDevice.

from MassDevice http://ift.tt/2nsNg8S